Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  STADA Arzneimittel    SAZ   DE0007251803

STADA ARZNEIMITTEL (SAZ)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/10/2018 07/11/2018 07/12/2018 07/13/2018 07/16/2018 Date
81.4(c) 80.9(c) 81.12(c) 81.5(c) 81.68(c) Last
42 969 22 725 12 747 20 688 20 279 Volume
+0.74% -0.61% +0.27% +0.47% +0.22% Change
More quotes
Financials (EUR)
Sales 2018 2 446 M
EBIT 2018 353 M
Net income 2018 210 M
Debt 2018 1 136 M
Yield 2018 0,95%
Sales 2019 2 577 M
EBIT 2019 383 M
Net income 2019 236 M
Debt 2019 936 M
Yield 2019 1,11%
P/E ratio 2018 26,58
P/E ratio 2019 22,39
EV / Sales2018 2,54x
EV / Sales2019 2,34x
Capitalization 5 081 M
More Financials
Company
STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products.It operates through the Generics and Branded Products segments.The Generics segment produces and distributes generic drugs.The Branded Products segment sells branded healthcare products and medicines.The... 
Sector
Pharmaceuticals
Calendar
07/17Shareholder meeting
More about the company
Surperformance© ratings of STADA Arzneimittel
Trading Rating : Investor Rating :
More Ratings
Latest news on STADA ARZNEIMITTEL
07/16XBRANE BIOPHARMA : and STADA enter into a co-development agreement for Xlucane
AQ
07/12STADA ARZNEIMITTEL AG : Xbrane and STADA enter into a co-development agreement f..
EQ
07/11STADA ARZNEIMITTEL AG : Announcement of the results of the Tender Offer regardin..
EQ
06/29STADA ARZNEIMITTEL AG : Not for distribution to any u.s. person or in or into or..
EQ
06/28STADA ARZNEIMITTEL : Strategic expansion of OTC portfolio continues – STAD..
PU
06/28STADA ARZNEIMITTEL AG : Strategic expansion of OTC portfolio continues - STADA a..
EQ
06/28JOHNSON & JOHNSON : Stada buys rights to anti-dandruff shampoo Nizoral from J&J
RE
06/15STADA ARZNEIMITTEL : recovers top-selling product and will distribute the Parkin..
PU
06/08STADA ARZNEIMITTEL AG : Consent Solicitation for STADA Euro bond 2015/2022
EQ
06/07STADA ARZNEIMITTEL : Ex-dividend day for final dividend
FA
More news
Sector news : Generic Pharmaceuticals

- No features available -

More sector news : Generic Pharmaceuticals
4-Traders Strategies on STADA ARZNEIMITTEL 
STADA ARZNEIMITTEL - 2014
Bearish scenario preferred
SELL
STADA ARZNEIMITTEL - 2014
Into a recovery phase
BUY
More Strategies
Latest Tweets
07/12STADA Arzneimittel AG: Xbrane and STADA enter into a co-development agreement.. 
07/11STADA Arzneimittel AG: Announcement of the results of the Tender Offer regard.. 
06/29STADA Arzneimittel AG: NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO .. 
06/28STADA Arzneimittel AG: Strategic expansion of OTC portfolio continues - STADA.. 
06/15STADA Arzneimittel : recovers top-selling product and will distribute the Par.. 
More tweets
Qtime:30
News from SeekingAlpha
05/05Stada Arzneimittel's (STDAF) CEO Claudio Albrecht on Q1 2018 Results - Earnin.. 
05/03Stada Arzneimittel AG 2018 Q1 - Results - Earnings Call Slides 
05/03Stada Arzneimittel AG reports Q1 results 
03/09Stada Arzneimittel's (STDAF) CEO Claudio Albrecht on Q4 2017 Results - Earnin.. 
03/08Stada Arzneimittel AG 2017 Q4 - Results - Earnings Call Slides 
Chart STADA ARZNEIMITTEL
Duration : Period :
STADA Arzneimittel Technical Analysis Chart | SAZ | DE0007251803 | 4-Traders
Technical analysis trends STADA ARZNEIMITTEL
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 6
Average target price 68,2 €
Spread / Average Target -17%
EPS Revisions
Managers
NameTitle
Claudio Albrecht Chairman-Executive Board
Günter von Au Chairman-Supervisory Board
Mark Burgess Keatley Chief Financial Officer
Miguel Pagan Fernandez Chief Technical Officer
Halil Duru Member-Supervisory Board
Sector and Competitors